See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, used to improve glycemic control in adults with type 2 diabetes, in addition to diet and exercise [1]. The recommended dosing schedule for Ozempic is as follows:

1. Initiate treatment with Ozempic 0.25 mg subcutaneously once a week for at least 4 weeks.
2. After 4 weeks, increase the dosage to Ozempic 0.5 mg subcutaneously once a week, if a higher dose is needed.

It is important to note that Ozempic should be administered subcutaneously in the abdomen, thigh, or upper arm, and the injection site should be rotated [1].

Regarding the timing of the doses, the prescribing information for Ozempic does not specify a particular time of day for administration. However, it is recommended to consistently administer Ozempic at the same time each day [1].

For more information on Ozempic, you can refer to DrugPatentWatch.com [2].

Sources:

1. "Ozempic (semaglutide) injection, for subcutaneous use [Prescribing Information]. Novo Nordisk Inc." <https://www.novo-pi.com/ozempic.pdf>.
2. "Ozempic (semaglutide) Drug Profile." DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/ozempic>.